Leukemia-initiating cells reside within the bone marrow in specialized niches where they undergo complex interactions with their surrounding stromal cells. We have identified the actin-binding protein Plastin-3 (PLS3) as potential player within the leukemic bone marrow niche and investigated its functional role in acute myeloid leukemia. High expression of PLS3 was associated with a poor overall and event-free survival for AML patients. These findings were supported by functional in vitro and in vivo experiments. AML cells with a PLS3 knockdown showed significantly reduced colony numbers in vitro while the PLS3 overexpression variants resulted in significantly enhanced colony numbers compared to their respective controls. Furthermore, the survival of NSG mice transplanted with the PLS3 knockdown cells showed a significantly prolonged survival in comparison to mice transplanted with the control AML cells. Further studies should focus on the underlying leukemia-promoting mechanisms and investigate PLS3 as therapeutic target.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895973 | PMC |
| http://dx.doi.org/10.3390/cancers11111663 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cytoskeleton dysfunction of motor neuron in spinal muscular atrophy.
J Neurol
December 2024
Department of Orthopedics, The Second Affiliated Hospital of Soochow University, No. 1055, Sanxiang Road, Suzhou, 215004, Jiangsu, China.
Spinal muscular atrophy (SMA) is a neurodegenerative disease caused by deletions or mutations of survival of motor neuron 1 (SMN1) gene. To date, the mechanism of selective cell death of motor neurons as a hallmark of SMA is still unclear. The severity of SMA is dependent on the amount of survival motor neuron (SMN) protein, which is an essential and ubiquitously expressed protein involved in various cellular processes including regulation of cytoskeletal dynamics.
View Article and Find Full Text PDFEditorial: Bone cell differentiation in health and disease, volume II.
Front Endocrinol (Lausanne)
November 2024
Tennessee Valley Healthcare System, Department of Veterans Affairs, Nashville, TN, United States.
Label-free quantitative proteomic profiling reveals differential plasma protein expression in patients with obesity after treatment with liraglutide.
Front Mol Biosci
September 2024
Proteomics Resource Unit, Obesity Research Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Article Synopsis
- The study explored the effects of the GLP-1 receptor agonist liraglutide on plasma protein profiles in patients with obesity, finding significant changes in weight, BMI, and HbA1c after three months of treatment.
- A total of 151 proteins showed significant dysregulation, with 31 being upregulated and 120 downregulated post-treatment, highlighting potential biomarkers like Cystatin-B and multimerin-2.
- Pathway analysis revealed major signaling pathways involved, particularly MAPK, AKT, and PKc, which play a crucial role in cell communication and could inform future obesity treatments.
Early-Onset Osteoporosis: Molecular Analysis in Large Cohort and Focus on the PLS3 Gene.
Calcif Tissue Int
November 2024
Rare Disease Genomic Medicine Department, CHU Necker-Enfants Malades, INSERM UMR1163, Institut Imagine, Université Paris-Cité, Paris, France.
Article Synopsis
- Osteoporosis is a skeletal disorder leading to increased fracture risk, and when it affects young individuals, it often indicates genetic causes related to early-onset osteoporosis (EOOP).
- Over 577 patients with primary osteoporosis were studied using next-generation sequencing of 21 bone fragility-related genes, revealing that around 18% had a genetic basis, primarily linked to the LRP5 gene.
- A rare finding included 17 patients with a variant in the PLS3 gene, suggesting the involvement of dominant X-linked osteoporosis, predominantly affecting males, but also identified severe cases in females, pointing toward possible genetic interactions.
Association among biomarkers, phenotypes, and motor milestones in Chinese patients with 5q spinal muscular atrophy types 1-3.
Front Neurol
September 2024
Department of Medical Genetics, Capital Institute of Pediatrics, Beijing, China.
Background: Biomarkers can be used to assess the severity of spinal muscular atrophy (5q SMA; SMA). Despite their potential, the relationship between biomarkers and clinical outcomes in SMA remains underexplored. This study aimed to assess the association among biomarkers, phenotypes, and motor milestones in Chinese patients diagnosed with SMA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!